Inovio Investors Get Derivative Deal OK'd Over Vaccine Claims

By Emilie Ruscoe · June 15, 2023, 9:12 PM EDT

Investors in biotechnology firm Inovio Pharmaceuticals Inc. have received an initial green light from a Philadelphia federal judge for their agreement to settle their derivative action against the company's brass over...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

BEHESHTI v. KIM et al

Case Number

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Securities/Commodities

Date Filed

April 20, 2020

Recent Articles By Emilie

May 15, 2025
Ex-CEO Cops To Conspiracy Charge In $212M Fraud Case
May 14, 2025
Actinium Faces Derivative Suit Over FDA Application Claims
May 13, 2025
Health Co. Elevance Faces Suit Over Post-COVID Costs Claims
April 29, 2025
Acadia Investors Seek Partial Win, Sanction In Healthcare Suit
March 24, 2025
Investors Blame Electrotherapy Co.'s Practices For Stock Drop
January 07, 2025
Obesity Drug Maker Faces Investor Suit Over IPO Disclosures
January 06, 2025
Biotech Co. Revance Faces Suit After Tender Offer Weakens
January 02, 2025
Eye Drug Study Blindsided Pharma Co. Investors, Suit Says
December 16, 2024
Ginkgo Bioworks Investors Get Final OK Of $17.8M Settlement
December 13, 2024
Pharma Co. Brass Face Investor Suit Over Drug Trial Probe